The two companies announced on 25 July 2013 that following a strategic review of the joint venture, they have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars, which was established in 2009.

While both companies intend to continue to explore opportunities to maximize the value of the investments and progress that the joint venture has made to this point, the companies report that the discontinuation of the joint venture will enable both companies to better advance their own strategies.

Teva, according to Dr Michael Hayden, President, Global R & D and CSO of Teva, intends to build on its track record of success in the biologicals field. Ending the joint venture will enable Teva to maintain a highly selective approach in the company’s efforts to create a balanced portfolio of biosimilars, biobetters and innovative biologicals that aligns with Teva’s overall portfolio and areas of disease focus, enabling the company to better serve patients. Lonza, on the other hand, intends to focus on its core expertise of contract manufacturing and cell line development.

Related articles

Lonza not backing out on biosimilars

Lonza/Teva biosimilar pact in jeopardy

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.